Date: 2016-09-01
Type of information: Company acquisition
Acquired company: VRL Laboratories (USA - CO)
Acquiring company: Eurofins Scientific (Luxembourg)
Amount: undisclosed
Terms:
- • On September 1, 2016, Eurofins announced the acquisition of VRL Laboratories, one of the leading laboratories in pre-transplant testing for the eligibility determination for donors of human cells, tissues, and cellular and tissue-based products in the US.
Details:
- Founded in 2010, VRL has become a reference laboratory solely focused on donor eligibility testing and microbiology testing for the transplant and medical communities. The company offers a broad menu of infectious disease screening assays to support the FDA’s 21 CFR 12711 donor eligibility determination testing requirements, specifically for eye, tissue, organ, stem cell and cord blood, as well as reproductive tissues. VRL employs a total of 60 staff across its main facility in Denver CO, and its satellite laboratories in Boston, MA, Dallas, TX, and Atlanta, GA.
- The acquisition of VRL reinforces Eurofins’ footprint in specialty clinical testing services and consolidates the Group’s leadership in the transplantation testing market. VRL’s microbiology testing services also expands Eurofins’ testing portfolio and increases client penetration in the transplantation testing market. In return, VRL will have access to the Group’s clients and competencies, as well as its laboratory network infrastructure, which should support its further development. In combination with ViraCor and Diatherix, VRL reinforces Eurofins' footprint in the testing market for transplantation and infectious diseases.
Related: Technology - Services
Is general: Yes
